Ulcerative Colitis
📧 Sign up to get email alerts when something new happens for Ulcerative Colitis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-03-30EMA Authorised: Uzpruvo (ustekinumab) — Stada Arzneimittel AG
EMA authorised Uzpruvo (ustekinumab) for the treatment of psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
-
EMA approval · 2026-03-25EMA Authorised: Otulfi (ustekinumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Otulfi, a ustekinumab product from Fresenius Kabi Deutschland GmbH, for Crohn's disease and Ulcerative colitis.
-
EMA approval · 2026-03-19EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
EMA authorised Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, expanding treatment options in rheumatoid …
-
FDA approval · 2026-03-06FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ XR (tofacitinib) from Pfizer Laboratories Div Pfizer Inc, introducing the extended-r…
-
EMA approval · 2026-03-05EMA Authorised: Simponi (golimumab) — Janssen Cilag International NV
The European Medicines Agency authorised Simponi (golimumab) for multiple inflammatory conditions including rheumatoid arthritis, psoriatic …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-03EMA Authorised: Zeposia (ozanimod hydrochloride) — Bristol-Myers Squibb Pharma EEIG
The EMA has authorised Zeposia (ozanimod hydrochloride) for relapsing-remitting multiple sclerosis and ulcerative colitis; the marketing aut…
-
EMA approval · 2026-03-03EMA Authorised: Entyvio (vedolizumab) — Takeda Pharma A/S
The European Medicines Agency authorised Entyvio (vedolizumab) for the treatment of ulcerative colitis and Crohn's disease, with Takeda Phar…
-
FDA approval · 2026-02-25FDA Approved: ENTYVIO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ENTYVIO (vedolizumab) submitted by Takeda Pharmaceuticals America, Inc., to support an expanded …
-
EMA approval · 2026-02-25EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
The EMA authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, juvenil…
-
EMA approval · 2026-02-19EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
The EMA authorised Hulio, a biosimilar of adalimumab, for multiple inflammatory indications including hidradenitis suppurativa, psoriasis, u…
-
EMA approval · 2026-02-17EMA Authorised: Inflectra (infliximab) — Pfizer Europe MA EEIG
EMA authorised Inflectra (infliximab) as a biosimilar to Remicade for multiple inflammatory diseases including rheumatoid and psoriatic arth…
-
EMA approval · 2026-02-05EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) as a biosimilar of adalimumab for several inflammatory and autoimmune diseases, including rheumatoid art…
-
EMA approval · 2026-02-04EMA Authorised: Imraldi (adalimumab) — Samsung Bioepis NL B.V.
EMA authorised Imraldi, a biosimilar adalimumab by Samsung Bioepis NL B.V., for multiple inflammatory diseases including ankylosing spondyli…
-
EMA approval · 2026-01-28EMA Authorised: Omvoh (mirikizumab) — Eli Lilly Nederland B.V.
EU authorised Omvoh (mirikizumab) for ulcerative colitis; Eli Lilly Nederland B.V. is the marketing authorisation holder.
-
EMA approval · 2026-01-28EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EMA authorised Hukyndra (adalimumab) from Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, psoriati…
-
EMA approval · 2026-01-19EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Skyrizi (risankizumab) for multiple indications. This expands its approved uses to psoriasis, psoriatic arthritis, ulcera…
-
FDA approval · 2026-01-07FDA Approved: YESINTEK — Supplemental Application (Biocon Biologics Inc.)
The FDA approved a supplemental application for YESINTEK (ustekinumab) from Biocon Biologics Inc. The action relates to the ustekinumab bios…
-
EMA approval · 2025-12-15EMA Authorised: Remicade (infliximab) — Janssen Cilag International NV
The EMA has authorised Remicade (infliximab) for multiple inflammatory diseases under Janssen Cilag International NV as the marketing author…
-
EMA approval · 2025-12-11EMA Authorised: Hyrimoz (adalimumab) — Sandoz GmbH
EMA authorised Hyrimoz (adalimumab) by Sandoz GmbH as a biosimilar to Humira for multiple inflammatory diseases, including rheumatoid arthri…
-
FDA approval · 2025-12-01FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for SELARSDI (USTEKINUMAB-AEKN), a biosimilar to ustekinumab.
-
EMA approval · 2025-11-21EMA Authorised: Usgena (ustekinumab) — Stada Arzneimittel AG
The European Medicines Agency authorised Usgena, a ustekinumab product from STADA, for treatment of Crohn's disease, psoriasis, psoriatic ar…
-
EMA approval · 2025-11-21EMA Authorised: Pyzchiva (ustekinumab) — Samsung Bioepis NL B.V.
EMA authorised Pyzchiva (ustekinumab) for Crohn's disease, ulcerative colitis, and psoriatic arthritis.
-
FDA approval · 2025-11-20FDA Approved: IMULDOSA — Supplemental Application (Accord BioPharma Inc.)
FDA approved a supplemental application for IMULDOSA (USTEKINUMAB-SRLF) from Accord BioPharma Inc. The action updates the regulatory status …
-
EMA approval · 2025-11-20EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited
The EMA authorised Gobivaz (golimumab) for multiple inflammatory diseases. Indications include rheumatoid arthritis, juvenile idiopathic art…
-
FDA approval · 2025-11-19FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for SELARSDI (ustekinumab-aeKn) from Teva Pharmaceuticals USA, Inc. The product is a ustekinumab bio…